MRT-2359 Shows Favorable Tolerability in Heavily Pretreated MYC-Driven Solid Tumors
MRT-2359 had acceptable tolerability with a favorable pharmacokinetic and pharmacodynamic profile in heavily pretreated patients with MYC-driven solid tumors, including lung cancer and high-grade neuroendocrine cancer.
Markus Warmuth Monte Rosa Therapeutics Mrt 2359 Patients With Myc Driven Solid Tumors Lung Cancer High Grade Neuroendocrine Cancer
Source: onclive.com